Research Paper Volume 15, Issue 11 pp 4963—4985
FDX1 serves as a prognostic biomarker and promotes glioma progression by regulating the immune response
Figure 6. Correlation of FDX1 expression with immune cells and immunotherapy. (A–I) Scatter plot indicating the association between FDX1 and macrophages (M0, M1, and M2), monocytes, activated CD4 memory T cells, CD8 T cells, gamma delta T cells, activated NK cells, and resting CD4 memory T cells. (J–M) Correlation between FDX1 and immunotherapy response using TIDE, dysfunction, exclusion, and MSI.